Landry Benjamin sold $141K of HCAT

Landry Benjamin (General Counsel) sold 99,478 shares of Health Catalyst, Inc. (HCAT) at an average of $1.42 ($1.39–$1.43, $0.14M total) across 2 trades over 2026-11-11 to 2026-11-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Landry Benjamin
Published Nov 13, 2026, 9:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 10:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HCAT
Bearish
medium confidence
Mentioned
$HCAT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HCATBearishLow
01

Why it matters

The disclosed sale is modest in size and likely to have limited effect on HCAT's share price, though it may add slight negative bias.

02

Market read

A routine insider sale with limited market impact; traders may monitor for any follow‑on activity but no immediate action is required.

03

What to watch

The 10b5‑1 plan suggests the sale was pre‑scheduled, reducing the informational content of the transaction.

Relevance 3/10Novelty 3/10Timing: after‑hours filing

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$HCATBearishMedium confidence
Context

General Counsel Landry Benjamin sold ~99,500 shares for $141K via a 10b5‑1 plan, reducing his stake to 251,894 shares.

Expected impact

likely slight downward pressure as investors price in the insider sell.

Evidence & confidence

Insider sales, especially by a senior officer, often lead to modest negative sentiment; the transaction size is small relative to market cap.

Market effects

Minimal impact on the health‑tech sector; the sale is company‑specific.

None

None

Counterpoint

The sale could be routine under a pre‑arranged plan and not indicative of any fundamental issue.

Key entities

  • Health Catalyst, Inc.

    Provider of data and analytics platforms for healthcare organizations.

  • Landry Benjamin

    General Counsel of Health Catalyst, executing a 10b5‑1 sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HCATMed

Health Catalyst Reports Third Quarter 2026 Results

Health Catalyst, Inc. (HCAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Health Catalyst Reports Third Quarter 2026 Results SALT LAKE CITY, UT, November 5, 2026 — Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today reported finan

$HCATMedAI 8/10

Health Catalyst (HCAT) Q2 2026 Earnings Call Transcript

Health Catalyst (HCAT) reported Q2 2026 revenue of $70.5M, down 13% from $80.7M a year earlier. Technology revenue fell to $48.8M and professional services to $21.7M. The company completed the Vitalware divestiture for $147M cash and repaid about $160M of debt. FY2026 guidance: revenue $246M-$249M and adjusted EBITDA $18M-$18.5M.

$HCATHighAI 9/10

Why Health Catalyst (HCAT) Shares Are Trading Lower Today

Health Catalyst (NASDAQ: HCAT) shares fell 23.1% after the company issued a weak Q3 revenue forecast and cut its full-year outlook. It expects Q3 revenue of $55.5 million versus $70.49 million in Q2, and reduced 2026 revenue guidance to $247.5 million at the midpoint. Q2 revenue met expectations, but the outlook pressured the stock.